Cis-diammine dichloroplatinum(DDP) is a new anti-tumor agents. In recent years it has been used for the therapy of solid tumors including squamous cell carcinoma and other malignancies of the head and neck. Cis-platinum is one of the most clinically beneficial anti-caner drugs used in combination regimens due to producing higher remission rates than single agent. But its use has been limited clinically due to many toxic effects including ototoxicity and nephrotoxicity. So, the authors studied about ototoxicity, nephrotoxicity, hematologic change and serum electrolyte change after Cis-platinum therapy by comparing the level before chemotherapy in 49 patient admitted to Dept. of Gynecology of Hanyang University Hospital because of gynecologic malignancy. Each patient was received one of three chemotherapy methods. 1) Cis-platinum, Adriamycin and Cytoxan(PAC). 2) Vinblastin, Bleomycin and Cis-platinum(VBP). 3) Cis-platinum only. The following results were obtained. 1) Mild ototoxicity at 2KHz, 4KHz, 8KHz level was seen in 12 out of 47 patients(25.53%). 35 patients(74.47%) was unaffected. The mean age of the affected patient was 48.3yr (range, 27 to 67yr), whereas that of the unaffected patient was 48.2yr(range, 2 to 70yr). 2) There were no significant change in hearing after 1 cycle infusion of Cis-platinum. 3) Significant threshold shift was observed at 4KHz and 8KHz of increasing cumulative dosage in PAC and 2KHz and 4KHz in patient who a cumulative dosage of 150mg/m² in VBP, who 300mg/m² in Cis-platinum only. 4) The first significant threshold shift was at 8KHz when the dosage was above 250mg/m² in Cis-platinum only. 5) The majority of patients did not have nephrotoxicity but two patients had a serum creatinine above 2.0mg% and BUN 20mg%. One case was appeared on combination therapy with VBP and the other with Cis-platinum only. 6) Leukopenia less than 3,000/mm³ in 6 patients(37.5%) and thrombocytopenia less than 100,000/mm³ in patients(18.8%) were noted in Cis-platinum only group. 7) Hypokalemia less than 3.5mEq/L after hydration with the infusion of Cis-platinum was noted in 2 patients(4.3%) in PAC. Judging from the results of this study above mentioned ototoxicity caused by Cis-platinum of the combined chemotherapy can be reduced by using mannitol diuresis and hydration. It should be used carefully to the patient with sensorineural or conductive hearing loss and repeated audiometry tests were required during treatment.